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Abstract
Background: Despite the regenerative capability of skeletal tissue fracture, non-union is common. Treatment of
non-unions remains challenging, and early determination of the outcome is impossible. Chemokines play an
important role in promoting the formation of new bone and remodeling existing bone. Despite their importance
regarding the regulation of bone biology, the potential of chemokines as biological markers reflecting osseous
regeneration is unknown.
The purpose of this study was to determine (1) if serum chemokine expression levels correlate with the outcome of
non-union surgery and (2) if chemokine expression analysis can be used to identify patients at risk for treatment failure.
Methods: Non-union patients receiving surgical therapy in our institution between March 2012 and March 2014 were
prospectively enrolled in a clinical observer study. Regular clinical and radiological follow-up was conducted for
12 months including collection of blood during the first 12 weeks. Based on the outcome, patients were declared as
responders or non-responders to the therapy. To minimize biases, patients were matched (age, sex, body mass index
(BMI)) and two groups of patients could be formed: responders (R, n = 10) and non-responders (NR, n = 10). Serum
chemokine expression (CCL-2, CCL-3, CCL-4, CXCL-10, CCL-11, and interferon gamma (IFN-γ)) was analyzed using
Luminex assays. Data was compared and correlated to the outcome.
Results: CCL-3 expression in NR was significantly higher during the course of the study compared to R (p = 0.002), and
the expression pattern of CCL-4 correlated with CCL-3 in both groups (NR: p < 0.001 and r = 0.63). IFN-γ expression in
NR was continuously higher than in R (p < 0.001), and utilization of CCL-3 and IFN-γ serum expression levels 2 weeks
after the treatment resulted in a predictive model that had an AUC of 0.92 (CI 0.74–1.00).
Conclusion: Serum chemokine expression analysis over time is a valid and promising diagnostic tool. The chemokine
expression pattern correlates with the outcome of the Masquelet therapy of lower limb non-unions. Utilization of the
serum analysis of CCL-3 and IFN-γ 2 weeks after the treatment resulted in an early predictive value regarding the
differentiation between patients that are likely to heal and those that are prone to high risk of treatment failure.
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Background
Bone is one of the few tissues that can heal without a fi-
brous scar, thereby osseous healing is considered as a
form of tissue regeneration [1]. The osseous healing cas-
cade is a complex physiological process involving mul-
tiple parameters both on a molecular and cellular level
[1, 2] that need to act concertedly. Aberrations in this
biological process can result in delayed healing or in the
development of a non-union [1]. Despite the regenera-
tive capability of skeletal tissue, fracture non-union is a
common (up to 30% of fractures fail to heal) and persist-
ent complication [3, 4]. Treatment of non-unions re-
mains a challenge in orthopedics and trauma surgery [4]
while multiple treatment modalities have been intro-
duced lately. The Masquelet therapy was established as a
safe and clinically effective treatment modality in the
treatment of large non-unions [5]. Despite studies show-
ing satisfying clinical results subsequent to the Masque-
let therapy [6, 7], early determination of the outcome
remains impossible. At present, the outcome is usually
assessed as early as 6 months after surgery based on
radiologic findings that require ionizing radiation (com-
puted tomography and X-rays) [8]. In addition, no valid
marker exists identifying patients that are prone to high
risk of treatment failure. Early identification of those
patients at risk would assist treating physicians in the
postoperative management and provide a rationale for
adjunct non-union treatment or timely revision surgery.
Chemokines are a family of signaling proteins secreted
by cells that are specific to vertebrates [9]. They can be
assigned to two major subfamilies: CXC (C–X–C motif )
and CC (C–C motif ) chemokine [10]. Members of these
subfamilies play an important role in bone biology [9]
and promote bone formation developmentally and in re-
sponse to mechanical stimuli [11]. In particular, they
modulate the formation of new bone and remodeling of
existing bone by coordinating cellular homing, osteo-
blastogenesis, and osteoclastogenesis [10]. Due to their
important role regarding the regulation of bone biology,
recent research focus has shifted towards several chemo-
kines and their mechanisms of action associated with
bone remodeling [10]. Thus, exploration of chemokines
as biological markers reflecting osseous regeneration
seems natural.
In previous studies [11, 12], the serum cytokine ana-
lysis was established as a valid method investigating into
biological processes occurring during bone regeneration
subsequent to non-union therapy. Hence, this study was
aimed to determine primarily if serum cytokine expres-
sion levels of distinct chemokines correlate with the out-
come of non-union surgery. Secondly, the possibility to
determine a prognostic model regarding the outcome of
non-union therapy based on the expression levels of
chemokines was investigated. Due to their importance in
bone healing, CCL-2, CCL-3, CCL-4, CXCL-10, CCL-11,
and interferon gamma (IFN-γ) [9, 10, 13, 14] were in-
cluded and analyzed. The hypothesis of the study was
that the expression patterns of distinct cytokines correl-
ate with bone regeneration occurring during non-union




To answer the research questions, a prospective clinical
observer study was performed. The study was conducted
at the Department of Orthopedics and Traumatology at
the Heidelberg University Hospital (a level 1 trauma
center). A total of 207 patients suffering from long-bone
non-union and receiving surgery between March 2012
and March 2014 in our department were enrolled in the
study. Due to the highly sensitive chemokine measure-
ment, strict inclusion and exclusion criteria were applied
and ultimately patients were matched in order to reduce
confounders and influences onto the results of this
study. Inclusion of patients started after approval of the
local institutional ethics committee (S-636/2011). In
addition, the study was conducted in accordance with
the latest version of the Declaration of Helsinki.
Inclusion and exclusion criteria
Patients suffering from failed bone healing after diaphy-
seal fractures of the tibia or femur that were between 18
and 80 years old and gave a written declaration of con-
sent were included in the study. Initially, patients that
were unable or unwilling to give a written consent, suf-
fering from chronic inflammatory diseases or malignan-
cies, needed to take immunosuppressive medication, or
suffered from renal or hepatic failure were excluded
from the study. In addition, patients that required add-
itional surgical interventions or re-revisions were ex-
cluded during the course of the study.
Rationale for group assignment
Patients that failed to show consolidation within
12 months after the second step of the Masquelet therapy
were determined as non-responders, whereas patients that
showed proper consolidation were determined as re-
sponders. Based on the outcome, patients were matched
based on three established criteria (age, sex, and BMI)
[11] and two groups were formed:
1. Responders to the therapy (group: R/N = 10)
2. Non-responders to the therapy (group NR/N = 10)
If more than one match was found for a patient, then
the patient with the most similar type of non-union was
chosen (Table 1).
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Intervention
According to the “diamond concept” [15], there are sev-
eral core factors necessary to achieve fracture consolida-
tion and bone regeneration [15] (vascularity, growth
factors, mechanical stability, osteogenic cells, and osteo-
conductive scaffolds). The Masquelet therapy, also called
induced membrane technique, was specifically designed
to treat challenging non-unions [5] by enhancing local
bone biology and inducing osseous regeneration via two
steps [5, 16]. In the initial surgical treatment (step I), the
non-union tissue, surrounding avital bone and avital sur-
rounding soft tissue, is debrided leaving a defect site. In
the same surgery, this defect is filled with polymethyl
methacrylate (PMMA) that is impregnated with antibi-
otics. The emerging foreign body reaction induces the
vascularized Masquelet membrane [17]. Harvesting of
tissue samples occurs during the first step that is subse-
quently microbiologically examined. The first step is
repeated until asepsis is achieved and guaranteed by
negative microbiological results, and afterwards, the spa-
cer is left in situ for 6 weeks to enable a fully grown
Masquelet membrane [18]. In a second step, the spacer is
removed while leaving the membrane intact and the de-
fect site is filled with a combination of autologous bone
graft and additional growth factors (3.3 mg of bone mor-
phogenetic protein 7) [5, 18–20]. De novo osteosynthesis
is performed during the first or second step based on the
anatomical localization and morphology of non-union.
Thereby, the Masquelet therapy provides all factors neces-
sary for bone healing according to the “diamond concept.”
Postoperative care and determination of outcome
According to previously published protocols [6, 11, 12],
clinical and radiologic examination was performed as
part of a dedicated follow-up program. In addition, pa-
tient data was thoroughly assessed preoperatively and
during each follow-up visit. Examination occurred prior
and 2 days as well as 1 week subsequent to each step. In
addition, examination was performed 2, 4, and 6 weeks, as
well as 3, 6, and 12 months, after the second step. Blood
samples were collected until 3 months after the second
step of the treatment (Additional file 1: Figure S1). Pa-
tients included in the study were completing most of all
follow-up examination. However, due to unavailability, oc-
casionally, single isolated blood samples were not ob-
tained. Outcome was evaluated 12 months after the final
surgical treatment and based on radiologic signs of con-
solidation (bridging in three out of four cortices in con-
ventional X-rays) and mechanical stability and full
weight-bearing [21–23].
Sample acquisition and measurement
Venous blood samples were taken (S Monovette 7.5 ml,
Sarstedt AG, Germany) from all patients following a
highly standardized previously published protocol [12].
Analysis of C-reactive protein (CRP) and leukocytes was
conducted directly after the blood was drawn. The quan-
titative analysis was performed with Luminex Perform-
ance Human High Sensitivity Assays (Quantikine®, RD
Systems, Minneapolis, MN, USA) strictly according to
the manufacturer’s instructions. The lab technician per-
forming the Luminex assays was blinded to both patient
data and clinical outcome.
Determination of sample size
Prior to commencement of the study, sample size deter-
mination was performed based on previously published
data [24]. In particular, the sample size calculation for
this study was performed in R [3.2.3] using the package
“pwr.” Assuming an alpha level of .05 and a power of .80
as well as an equal number of subjects in the experimen-
tal and control groups, 9.41 patients per group were esti-
mated to be required. Thus, a total of 10 patients per
group were included.
Patients demographics
Forty-nine patients were eligible for the current study
(Fig. 1). According to our established matched-pair ana-
lysis, a total of 20 non-union patients were included into
the current study (8 females and 12 males). Included
Table 1 Patient characteristics




Male 12 6 6 p = 1.000
Female 8 4 4
Age 50.75 ± 11.49 50.8 ± 13.05 50.7 ± 10.40 p = 0.4277
BMI 30.08 ± 6.57 27.92 ± 6.45 32.235 ± 6.25 p = 0.3946
Smoking
S 8 3 5 p = 0.2865
NS 10 5 5
FS 2 2 0
Diabetes
Yes 3 1 2 p = 1.0000
No 17 9 8
Localization
Tibia 10 7 3 p = 0.1797
Femur 10 3 7
Fixation
Nail 8 3 5 p = 0.6481
Plate 12 7 5
Previous
surgeries
3.15 ± 2.03 2.5 ± 1.08 3.8 ± 2.57 p = 0.7715
S active smoker, NS nonsmoker, FS former smoker; age is presented in years
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patients were an average of 50.8 ± 11.5 years old. Statisti-
cally, patients of both groups had resembling characteris-
tics regarding gender, age, BMI, smoking habits, diabetes,
localization of the non-union, nail or plate fixation, and
count of previous surgeries. Further details regarding pa-
tient characteristics in each group can be found in Table 1.
Statistics
Explorative correlation analyses were conducted between
all cytokine variables. Nonparametric test methods were
assessed to investigate location shifts between groups
(Mann–Whitney U test). Categorical variables were evalu-
ated using the chi-square test. In order to assess if analysis
of the expression pattern of the measured chemokines
was able to predict the outcome of the therapy, multiple
binary logistic regression models were utilized. Patients
with incomplete data points were excluded from this ana-
lysis. Variables included were standardized. All initially
available clinical variables (e.g., sex, age) as well as any
serum parameters were included in the process to ensure
valid assessment of the additional predictive power of the
remaining potential covariates. Model selection was per-
formed via AIC (Akaike information criterion) compari-
son. Predictive performance was assessed by estimation of
the AUC (area under the curve) of the ROC (receiver op-
erating characteristic) curve and the corresponding confi-
dence interval. All p values quoted are to be interpreted in
a descriptive way as they were not adjusted for multiple
testing as this is an exploratory post hoc analysis. All stat-
istical calculations were performed with R version 3.2.3
Fig. 1 Flow diagram of the patient selection and exclusion process
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[25]. Figures were created by using the package “ggplot2”
[26]. Serum levels are expressed as absolute mean concen-
trations ± SEM (standard error of mean), and statistical
significance was determined as p < 0.05.
Results
Evaluation of inflammatory response
Independent inflammatory markers (CRP and leuko-
cytes) revealed a physiological expression pattern with-
out significant differences between groups. Both CRP
and leukocyte count returned to normal 4 weeks after
surgery (Table 2).
Evaluation of CCL-3 and CCL-4 serum expression
Following baseline expression, serum levels of CCL-3 in
R slightly decreased until reaching a minimum prior to
step II (18.51 ± 4.46 pg/ml); afterwards, expression in R
was continuously lower than in NR reaching its peek
4 weeks after the treatment (27.54 ± 6.01 pg/ml). Starting
2 days after the initial surgery, expression of CCL-3 in
NR was higher than in R throughout the study period.
Analysis showed that expression of CCL-3 6 weeks after
the treatment was significantly higher in NR compared
to R (p = 0.036). Additionally, combined expression of
CCL-3 in NR was significantly higher during the course
of the study compared to R (p = 0.002 (Fig. 2a)). The
expression pattern of CCL-4 was similar to the expres-
sion pattern of CCL-3 in both groups. Differences of
CCL-4 between groups were at a nonsignificant extent
(Fig. 2b). Expression pattern of CCL-3 and CCL-4 cor-
related significantly in NR to the therapy at 1 week
after the first step (p = 0.001), prior to the second step
(p = 0.047), and two days (p = 0.013) and one week after
the second step (p = 0.040).
Analysis of CCL-2 and CCL-11 serum expression
In R, the CCL-2 values were the highest prior to the sur-
gical treatment (preoperatively, 566.21 ± 56.35 pg/ml)
and the lowest two weeks after the second step (467.85
± 32.90 pg/ml). In contrast, mean CCL-2 values in NR
showed a minimum immediately after the first step
(409.29 ± 39.82 pg/ml) and peak serum levels were
reached 6 weeks following step II (608.23 ± 97.41 pg/ml).
Statistical analysis revealed that differences between
groups were at a nonsignificant extent during the course
of the study. Interestingly, similar to CCL-3 and CCL-4,
baseline expression of CCL-2 in R was higher compared
to NR (Fig. 3a). Four weeks after step II, serum values of
CCL-11 were significantly higher in responders to the
therapy (R, 402.45 ± 51.24 pg/ml vs. NR, 261.06 ±
12.65 pg/ml; p = 0.047). Interestingly, peak values of
CCL-11 in R were reached 3 months after the treatment
(406.54 ± 83.07 pg/ml), whereas peak values in NR oc-
curred 6 weeks after the treatment (351.51 ± 58.93 pg/
ml) (Fig. 3b).
Analysis of CXCL-10 and IFN-γ serum expression
CXCL-10 expression was slightly lower in R compared
to NR and differences being significant 1 week after the
initial treatment (p = 0.043). Expression was lowest in
both groups immediately after step I (R, 58.45 ±
10.33 pg/ml vs. NR, 62.81 ± 9.31 pg/ml). Interestingly,
expression in R showed a minimum immediately after
each surgical treatment, whereas expression in NR only
showed that minimum after the first step. Expression in
NR peaked 4 weeks after step II (127.65 ± 18.49 pg/ml)
and in R 2 weeks after the second step (108.94 ±
15.59 pg/ml) (Fig. 4a). Peak expression of IFN-γ in NR
was higher (2 weeks after the treatment: 10.21 ± 3.91 pg/
ml) compared to the peak reached in R (4 weeks after
the treatment: 4.07 ± 1.56 pg/ml). Afterwards, values de-
creased until the end of the study. Combined expression
of IFN-γ in NR was significantly higher than in R
(p < 0.001) (Fig. 4b).
Binary logistic modeling regarding the predictive power
Statistical analysis revealed that the best performing
model was the one including only CCL-3 and IFN-γ
serum expression levels 2 weeks after the second step of
the Masquelet therapy. Regarding its predictive capabil-
ities, the utilized model had an AUC of 0.92 (CI 0.74–
1.00) and the resulting ROC is depicted in Fig. 5.
Table 2 Analysis of independent infectious parameters
Group Measurement Time point
Pre-op step I 2 days 1 week Pre-op step II 2 days 1 week 2 weeks 4 weeks
Responders L (mean ± SEM in
1000/μL)
7.434 ± 0.56 8.376 ± 0.83 7.331 ± 0.91 7.17 ± 0.71 8.156 ± 1.11 7.54 ± 0.89 7.285 ± 1.66 7.005 ± 1.01
CRP (mean ± SEM
in mg/L)
8.74 ± 2.85 100.4 ± 12.82 32.35 ± 9.96 14.32 ± 4.99 97.3 ± 14.89 47.29 ± 10.56 38.25 ± 12.70 8.05 ± 6.05
Non-
responders
L (mean ± SEM in
1000/μL)
7.126 ± 0.52 7.391 ± 0.70 6.232 ± 0.47 6.559 ± 0.65 7.223 ± 0.70 6.952 ± 0.83 7.877 ± 1.50 5.53 ± 1.08
CRP (mean ± SEM
in mg/L)
9.06 ± 3.01 91.06 ± 12.44 35.33 ± 8.81 15.178 ± 9.06 105.275 ± 18.46 48.1 ± 8.72 15.033 ± 6.07 19.15 ± 13.95
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Fig. 2 Analysis of CCL-3 and CCL-4. The average concentration and SEM (pg/ml) of CCL-3 (a) and CCL-4 (b) are shown during both steps of
treatment and follow-up. Dark triangles display non-responders, and gray points indicate responders. Significant differences are indicated by a
star (p < 0.05). Abbreviations: preoperatively (P), postoperative days (D), and weeks (W)
Fig. 3 Analysis of CCL-2 and CCL-11. The average concentration and SEM (pg/ml) of CCL-2 (a) and CCL-11 (b) are shown during both steps of
treatment and follow-up. Dark triangles display non-responders, and gray points indicate responders. Significant differences are indicated by a
star (p < 0.05). Abbreviations: preoperatively (P), postoperative days (D), and weeks (W)
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Discussion
The findings of the current study provide important infor-
mation regarding both research questions. Serum chemo-
kine expression analysis over time of treatment is a valid
and promising novel tool in the analysis of the expression
pattern of distinct chemokines in context with non-union
therapy. This data indicates that the chemokine expres-
sion pattern correlates with the outcome of the Masquelet
therapy of lower limb non-unions. Ultimately, the analysis
of CCL-3 and IFN-γ 2 weeks after the second step was
able to identify patients that are at high risk for failure of
the treatment.
The initial phase of fracture healing and bone regener-
ation is characterized by its inflammatory character [1].
CCL-2, also called monocyte chemotactic protein-1
(MCP-1), and its receptor CCR2 have been shown to in-
duce the early inflammatory phase of tissue healing [27]
and therefore play an important role during the early
phase of fracture healing [27, 28]. Deletion of CCR2 only
in the early phase of fracture healing has caused delayed
fracture healing indicating the importance of increased
CCL-2 expression for normal fracture healing [27]. In
the current study, NR showed a minimum subsequent
to the initial surgical treatment, whereas values in R only
slightly decreased. The first step of the Masquelet ther-
apy is intended to induce a vascularized membrane via a
foreign body reaction [18, 29]. Interestingly, the foreign
body reaction is initiated by an inflammatory response
to the biomaterial similar to the response in early frac-
ture healing [30]. Lower levels of CCL-2 after the first
step in NR might correlate with an abnormal initial in-
flammatory response during the enfolding foreign body
reaction that influences the outcome of the following
bone regeneration.
Macrophage inflammatory protein 1 (MIP1) is a chemo-
kine subfamily consisting of four members [31]. Relevant
roles of CCL-3 expression, also called macrophage inflam-
matory protein 1 α (MIP1α), have been described for a
variety of diseases [31]. However, no evidence exists re-
garding the role of CCL-3 during bone regeneration. In
this study, beginning 1 week after the initial treatment,
CCL-3 levels were constantly higher in NR. This elevated
expression of CCL-3 might correlate with an increased os-
teoclastogenesis and active bone degradation resulting in
an unfavorable microenvironment regarding the integra-
tion of the bone graft. This postulation is supported by
findings from the literature. Expression of CCL-3 has been
described in context with osteoclastogenesis and osteolysis
[32]. Additionally, elevated expression of CCL-3 can be
found in aseptic implant loosening and osteomyelitis [32]
providing evidence of CCL-3 inducing differentiation of
monocytes to bone-resorbing osteoclasts [32]. In particu-
lar, strong evidence exists regarding CCL-3 expression
correlating with bone degeneration in patients with
Fig. 4 Analysis of CXCL-10 and IFN-γ. The average concentration and SEM (pg/ml) of CXCL-10 (a) and IFN-γ (b) are shown during both steps of
treatment and follow-up. Dark triangles display non-responders, and gray points indicate responders. Significant differences are indicated by a
star (p < 0.05). Abbreviations: preoperatively (P), postoperative days (D), and weeks (W)
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multiple myeloma providing proof regarding a link be-
tween CCL-3 activation and bone degradation [32–34].
Biological function of CCL-4, also called MIP1β, is closely
connected to CCL-3 [35]. Studies have shown that CCL-3
and CCL-4 are predominant factors responsible for the
enhancement of bone resorption in multiple myeloma
[36] and play a causal role in the development of lytic
bone lesions in vivo. In the current study, serum expres-
sion of CCL-4 correlated significantly with the expression
pattern of CCL-3. Thus, expression of CCL-4 was higher
in NR during most time of the study. This correlation sup-
ports previous findings by indicating that both CCL-3 and
CCL-4 act in concert.
CCL-11, also called eotaxin-1, is a chemokine that is
produced by a variety of cells including endothelial cells
and chondrocytes [37]. In mice suffering from an inflam-
matory bone resorption, CCL-11 expression was higher
compared to healthy controls [37], whereas in patients
with chronic nonbacterial osteomyelitis, CCL-11 expres-
sion was lower compared to healthy controls [38]. Inter-
estingly, the authors stated that expression of CCL-11
varied between different groups [38]. In bone regener-
ation subsequent to the Masquelet therapy, expression
of CCL-11 was similar during the initial 10 weeks of the
treatment. Hereafter, serum expression of CCL-11 was
significantly higher in patients that responded to the ther-
apy. Previous studies reported a chemokine-dependent
amplification loop in bone metabolism [38, 39]. In par-
ticular, in aseptic conditions, CCL-11 was expressed by
normal osteoblasts, while in inflammatory conditions, ele-
vated CCL-11 levels stimulated migration of osteoclast
precursors in addition to bone resorption [38]. Despite be-
ing initiated by an inflammatory response, bone regener-
ation in the current study occurred in aseptic conditions.
Therefore, higher levels of CCL-11 in responders during
bone integration might correlate with bone remodeling
necessary to integrate the graft. However, the exact nature
of this mechanism remains a speculation and is beyond
the scope of this report.
The chemokine CXCL-10 is induced by IFN-γ result-
ing in its alternative name interferon-gamma-inducible
protein 10 (IP-10) [40]. A relevant role for CXCL-10 was
Fig. 5 ROC of the predictive model. ROC of the binary regression model evaluating the predictive capabilities of the analysis of serum levels of
CCL-3 and IFN-γ 2 weeks after the second step. 95% CI marked as gray area in both directions
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shown for chronic Th1 inflammatory diseases [40]. In par-
ticular, serum levels of CXCL-10 were elevated in patients
suffering from a rheumatoid arthritis [40] and expression
of CXCL-10 caused the recruitment of inflammatory cells
and is involved in bone erosion in inflamed joints [41].
Interestingly, a recent study has shown increased CXCL-
10 levels in the acute graft-versus-host disease (aGvHD)
subsequent to bone marrow transplantation [42]. Thereby,
measurement of CXCL-10 was postulated as possible bio-
marker in context with aGvHD [42]. In the current study,
patients received autologous bone grafts and usually no
graft-versus-host response is expected. However, a syn-
drome similar to GvHD has been reported to occur spon-
taneously in 8% of patients receiving autologous bone [43].
Interestingly, expression of CXCL-10 was elevated in
non-responders in the initial 10 weeks of the treatment
and peak levels were reached subsequent to the implant-
ation of autologous bone graft. This elevated CXCL-10
might correlate with an abnormal response of the body to
the transplanted autologous bone graft resulting in failure
of the treatment. This altered host response regarding au-
tologous bone might pose as an interesting approach in
understanding factors influencing the outcome of bone re-
generation and warrants further investigation.
IFN-γ is the only type II interferon and was originally
associated with the host defense regarding a viral infection
[44]. However, substantial evidence exists regarding the
influence of IFN-γ onto bone healing. In particular, IFN-γ
decreased the bone healing capability of mesenchymal
stem cells (MSC) and MSC treated with IFN-γ underwent
apoptosis [44]. Thereby, an anti-osteogenic function was
associated with IFN- [44]. Another study showed that
IFN-γ and tumor necrosis factor alpha synergistically in-
duced MSC deficiency resulting in osteoporosis [44]. Au-
tologous bone graft induces bone healing due to its
osteoinductivity based on high concentrations of MSC
[15]. In this study, initial expression of IFN-γ was similar
during the first step of the treatment and only after the
transplantation of autologous bone values were higher in
non-responders to the therapy. These high levels of IFN-γ
might inhibit the function of MSCs in the implanted graft
causing an impaired osseous induction ultimately result-
ing in failure of the treatment.
Up to date, no valid biomarker exists capable of identify-
ing patients that are at risk for an unsuccessful non-union
treatment. Evaluation of the outcome relies on radiological
diagnostics that require radiation exposure [8], and earli-
est determination is achievable 6–12 months postopera-
tively. Recalcitrant non-unions are associated with a low
quality of life, long period of recovery, and strenuous sur-
gical treatments that eventually fail. As traditional X-ray
or CT scans are not able to determine the outcome at an
early stage, the resulting uncertainty represents a consid-
erable psychological burden for concerned patients. Thus,
an early prediction of the outcome might contribute to-
wards both an improved patient satisfaction and stratifica-
tion of the postoperative management regarding the
individual risk. In addition, early identification might
provide rationale for additional postoperative non-union
therapies, such as low-intensity pulsed ultrasound [45].
Results from this study introduced the measurement of
CCL-3 and IFN-γ 2 weeks subsequent to the second step
of the Masquelet therapy as promising novel diagnostic
modality. In particular, evaluation based on these bio-
logical markers had a high sensitivity and good specificity
in detecting patients at risk for poor outcome. Due to the
commercial availability of the used Luminex assays, the
low direct costs, and the short time necessary to perform
the analysis, this method is easy to both implement and
perform in all centers having a clinical laboratory. The
promising results of the current study are intended to en-
courage surgeons to evaluate this diagnostic modality in
their own setting. Ultimately, the findings of this study
might contribute towards an improved patient safety in
context with non-union therapy.
Despite relevant findings, our study has limitations.
Non-unions are a severe and clinically relevant complica-
tion, whereas absolute numbers remain relatively small. In
addition, serum cytokine and chemokine analysis are
highly sensitive and can be influenced by various factors;
therefore, a close matching of patients next to our strict
inclusion and exclusion criteria was used to reduce the
differences between groups. This explains the small pa-
tient collective of this study. In the context of current lit-
erature and recent studies [12, 46], the patient collective
size is still sufficient to provide reliable results. Results of
this study may be influenced by a systemic inflammation;
therefore, the CRP and leukocyte serum patterns were
assessed in the initial 4 weeks subsequent to the proced-
ure. The data showed comparable CRP values during the
course of the study in both groups; in addition, leukocytes
remained in a physiological range during the whole time,
thereby indicating that no systemic inflammation was
present. The current study provided first evidence regard-
ing the predictive capabilities of chemokine expression
analysis in context with non-union therapy. However, fur-
ther studies are needed that involve a larger non-matched
patient collective in order to assess the influence of indi-
vidual patient characteristics and establish a threshold for
the introduced CCL-3 and IFN-γ test.
Conclusions
The results of the current study introduce the serum
analysis of the expression pattern of distinct chemokines
as a novel diagnostic modality in context with bone re-
generation occurring during non-union therapy. As bone
regeneration occurs in the Masquelet therapy and the
treatment is both highly standardized and regularly
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monitored, this treatment has become valuable in study-
ing biological processes occurring during bone regener-
ation. The expression pattern of chemokines (CCL-2,
CCL-3, CCL-4, CCL-11, CXCL-10, and IFN-γ) correlates
with the outcome of the Masquelet therapy of lower
limb non-unions. Furthermore, the analysis of CCL-3
and IFN-γ serum levels 2 weeks after step II of the ther-
apy predicts the likelihood of successful induction of
bone regeneration during the Masquelet therapy and
provides an additional predictive value regarding the
early identification of patients that are at high risk for
failure of the treatment. Based on these results, the
current study introduces an early predictive value re-
garding the differentiation between patients that are
likely to heal and those that are at high risk for a poor
outcome.
Additional file
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to our standardized cytokine protocol. Clinical and radiological follow-up
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and radiological examinations in red. (PNG 5466 kb)
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